Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update

DUBLIN, April 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2020, and provided commentary related to the impact of the COVID-19 pandemic on the business.

"In the face of the COVID-19 pandemic, Alkermes has adapted our business practices so that we can both continue to operate safely and meet our public health responsibilities. People living with serious mental illness and addiction have an ongoing need for their medicines and care, yet many are facing challenges in accessing their caregivers and the healthcare system," said Richard Pops, Chief Executive Officer of Alkermes. "We immediately mobilized to change the way we do business to protect the health and wellbeing of our employees and maintain business continuity, including preserving our ability to provide uninterrupted supply of the medicines we manufacture. I am grateful and proud of the resiliency and adaptability demonstrated by employees across the company. In the next stage of our response, we are focusing on how we can learn from the challenges posed by this pandemic and be creative in developing new best practices that have the potential to have a lasting positive impact on our business."

"We entered 2020 with clear operational objectives: drive the growth of VIVITROL(®) and ARISTADA(®); prepare for the potential approval and launch of ALKS 3831; and advance our research and development portfolio, including the clinical development program for ALKS 4230 in oncology. We have made progress against all these objectives and our first quarter results reflect solid commercial execution for our proprietary products," continued Mr. Pops. "We will continue to adapt as needed in this dynamic environment to advance these key priorities. ALKS 4230 and ALKS 3831 represent the next major potential value drivers for the business. The potential of ALKS 4230 continues to be supported by the accumulating clinical data across our studies of both intravenous and subcutaneous administration in monotherapy and combination settings. We look forward to sharing data at a medical meeting later this year. For ALKS 3831, we will be finalizing our commercial launch planning as we approach the November 2020 PDUFA date. ALKS 3831 offers an important opportunity to drive operating leverage and efficiencies related to our existing psychiatry commercial infrastructure and drive long-term profitability."

Quarter Ended March 31, 2020 Financial Highlights

    --  Total revenues for the quarter were $246.2 million. This compared to
        $223.1 million for the same period in the prior year.
    --  Net loss according to generally accepted accounting principles in the
        U.S. (GAAP) was $38.7 million for the quarter, or a basic and diluted
        GAAP net loss per share of $0.24. This compared to GAAP net loss of
        $96.4 million, or a basic and diluted GAAP net loss per share of $0.62,
        for the same period in the prior year.
    --  Non-GAAP net income was $1.7 million for the quarter, or a non-GAAP
        basic and diluted earnings per share of $0.01. This compared to non-GAAP
        net loss of $26.0 million, or a non-GAAP basic and diluted net loss per
        share of $0.17, for the same period in the prior year.

Quarter Ended March 31, 2020 Financial Results


    --  Net sales of proprietary products were $129.7 million, compared to $99.5
        million for the same period in the prior year.
        --  Net sales of VIVITROL were $78.8 million, compared to $69.2 million
            for the same period in the prior year, representing an increase of
            approximately 14%.
        --  Net sales of ARISTADA(i) were $51.0 million, compared to $30.3
            million for the same period in the prior year, representing an
            increase of approximately 68%.
    --  Manufacturing and royalty revenues were $116.3 million, compared to
        $108.9 million for the same period in the prior year.
        --  Manufacturing and royalty revenues from RISPERDAL CONSTA(®), INVEGA
            SUSTENNA(®)/XEPLION(®) and INVEGA TRINZA(®)/TREVICTA(®) were
            $82.2 million, compared to $75.6 million for the same period in the
            prior year.

Costs and Expenses

    --  Total operating expenses were $283.6 million, compared to $299.1 million
        for the same period in the prior year.
        --  Research and Development (R&D) expenses were $93.3 million, compared
            to $102.6 million for the same period in the prior year.
        --  Selling, General and Administrative (SG&A) expenses were $133.4
            million, compared to $141.2 million for the same period in the prior

Balance Sheet

    --  At March 31, 2020, Alkermes recorded cash, cash equivalents and total
        investments of $549.7 million, compared to $614.4 million at Dec. 31,
        2019. Cash on hand at March 31, 2020 significantly exceeded the
        company's total debt outstanding of $276.6 million under its term loan,
        which matures in March 2023.

"Our first quarter results were slightly ahead of expectations, reflecting 30% year-over-year growth in net sales of our proprietary products, and continued focus on advancing our pipeline of novel oncology and neuroscience candidates," commented James Frates, Chief Financial Officer of Alkermes. "Due to the uncertain duration and extent of COVID-19 disruptions to the healthcare system, including patient access to treatment, we cannot reliably estimate the future impact that COVID-19 may have on our business and are withdrawing our 2020 financial expectations at this time. We remain focused on driving the growth of VIVITROL and ARISTADA, advancing our research and development activities, and maintaining disciplined expense management. We believe Alkermes is financially well-positioned, with sufficient capital and liquidity to weather the impacts of this pandemic. We will continue to take proactive steps to help ensure business continuity and advance our business objectives."

Financial Expectations for 2020

Due to uncertainties regarding the impact of the COVID-19 pandemic on Alkermes' operating and financial results, Alkermes withdraws the financial expectations for 2020 set forth in its press release dated Feb. 13, 2020. The company expects that the extent of the impact of COVID-19 on its business will be driven primarily by the severity and duration of the pandemic. While the company has adopted practices to mitigate the impact of COVID-19 disruptions, at this time, it is unable to reasonably estimate the impact of the pandemic on future results.

COVID-19 Update

Protection of Employee Well-Being

    --  The company has instituted a global remote work policy that will
        continue until further notice for those employees who can work remotely,
        including field-based employees. For those manufacturing and lab-based
        employees who work on critical research and manufacturing tasks, the
        company has instituted additional equipment, sanitization and physical
        distancing practices to help protect their health and safety as they
        continue to advance important research and deliver medicines for

Manufacturing & Supply

    --  At this time, the company continues to operate its manufacturing
        facilities in Wilmington, Ohio and Athlone, Ireland and does not
        anticipate any interruptions in its ability to supply commercial product
        to the patients that rely on VIVITROL, ARISTADA and the third-party
        products it manufactures, and investigational product for ongoing
        clinical trials. Together with its critical supply chain vendors, the
        company is working to continually assess and mitigate the potential
        impact of COVID-19 on Alkermes' manufacturing operations.

Supporting Patients & Healthcare Providers

    --  The company has taken action to support people living with
        schizophrenia, opioid dependence and alcohol dependence and help assure
        that they have access to the information, resources and medicines that
        may assist in their treatment. To support these efforts, the company is:
        --  identifying new healthcare providers who are currently available to
            administer injections of its medicines, including appropriate retail
            pharmacies and clinics;
        --  updating the provider locators on and with
            information on these healthcare providers and injection sites; and
        --  working closely with healthcare providers, including pharmacies, and
            payers to help navigate new challenges that may arise for patients
            in accessing their prescribed medications.
    --  For the safety of employees and in consideration of national and local
        guidelines, in mid-March the company suspended all in-person meetings
        and interactions with the healthcare community for field-based sales
        personnel. The company remains dedicated to supporting the needs of
        healthcare providers and patients through virtual interactions.

Research and Development

    --  Clinical trials: The company has been in frequent communication with
        investigators regarding the impact of the current environment on the
        conduct of its ongoing clinical trials and is focused on supporting
        treatment continuity and ensuring patient safety. While COVID-19 has
        impacted timelines of certain clinical trials, ongoing studies are
        continuing with the appropriate precautions, managed in consultation
        with investigators and academic institutions.
    --  Regulatory: At this time, the company continues its regulatory
        activities relating to ALKS 3831, including preparation for an Advisory
        Committee meeting in advance of the November 2020 Prescription Drug User
        Fee Act ("PDUFA") target action date for ALKS 3831.

Conference Call

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. BST) on Wednesday, April 29, 2020, through Wednesday, May 6, 2020, and may be accessed by visiting Alkermes' website or by dialing +1 877 660 6853 for U.S. callers and +1 201 612 7415 for international callers. The replay conference ID is 13701480.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Non-GAAP net income (loss) adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of our liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning future financial and operating performance, business plans or prospects, including the resilience of the company's business model and its ability to weather the financial impacts of the COVID-19 pandemic and the company's potential to drive long-term profitability and continued revenue growth from its commercial products and royalty streams; the potential therapeutic and commercial value of the company's marketed and development products; the company's expectations regarding the impact of COVID-19 on its business; the company's expectations regarding its ability to adapt its business to the evolving COVID-19 pandemic, mitigate its impacts on the business and maintain business continuity, including its ability to protect the safety and well-being of its employees, to continue to operate its manufacturing facilities and support uninterrupted supply of its medicines and patient and healthcare provider access to such medicines, to continue its ongoing clinical trials and other development activities, and to otherwise advance its business objectives; expectations concerning future regulatory activities including the U.S. Food and Drug Administration's ("FDA") target PDUFA action date for, and potential approval of, the NDA for ALKS 3831 and preparations for interactions with the FDA in advance thereof; expectations concerning future development activities, including accumulating data in the ALKS 4230 clinical development program in support of its potential and plans to present such data at a medical meeting; and expectations concerning the company's commercial activities, including preparations for the potential launch of ALKS 3831. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the impacts of the COVID-19 pandemic and efforts to mitigate its spread on the company's business, results of operations or financial condition, including impacts on the vendors or distribution channels in its supply chain, impacts on its ability to continue to manufacture its products, impacts on its ability to continue its discovery activities, impacts on the conduct of its clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites or monitoring of data, impacts on healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia and on patient and healthcare provider access to the company's medicines, impacts on the regulatory agencies with which the company interacts in the development, review, approval and commercialization of its medicines, impacts on reimbursement for its products, including its Medicaid rebate liability, and for services related to the use of its products, and impacts on the U.S., Irish and/or global economies more broadly; the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, related to any of the company's products or products using the company's proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than the company interprets it; the FDA may not agree with the company's regulatory approval strategies or components of its regulatory filings, including the company's clinical trial designs, conduct and methodologies and the adequacy of the data included in its filings to support the FDA's requirements for approval of the proposed indications; clinical development activities may not be completed on time or at all; the results of the company's clinical development activities may not be positive, or predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

VIVITROL(®) is a registered trademark of Alkermes, Inc.; ARISTADA(®) and ARISTADA INITIO(®) are registered trademarks of Alkermes Pharma Ireland Limited; and RISPERDAL CONSTA(®), INVEGA SUSTENNA(®), XEPLION(®), INVEGA TRINZA(® )and TREVICTA(®) are registered trademarks of Johnson & Johnson

(tables follow)


                 i            The term "ARISTADA" as used in this press release refers
                               to ARISTADA and ARISTADA INITIO, unless the context
                               indicates otherwise.

           Alkermes plc and Subsidiaries

       Selected Financial Information (Unaudited)

                Condensed Consolidated Statements of Operations - GAAP                                                                                    
         Three Months Ended      
        Three Months Ended

                (In thousands, except per share data)                                                                                                       
         March 31, 2020          
        March 31, 2019


       Product sales, net                                                                                                                                                                $129,726                            $99,481

       Manufacturing and royalty revenues                                                                                                                                                 116,251                            108,915

       Research and development revenue                                                                                                                                                       243                             14,706

       Total Revenues                                                                                                                                                                     246,220                            223,102


       Cost of goods manufactured and sold                                                                                                                                                 47,211                             45,361

       Research and development                                                                                                                                                            93,279                            102,570

       Selling, general and administrative                                                                                                                                                133,372                            141,220

       Amortization of acquired intangible assets                                                                                                                                           9,728                              9,952

       Total Expenses                                                                                                                                                                     283,590                            299,103

       Operating Loss                                                                                                                                                                    (37,370)                          (76,001)

       Other Income (Expense), net:

       Interest income                                                                                                                                                                      2,760                              3,570

       Interest expense                                                                                                                                                                   (2,857)                           (3,500)

       Change in the fair value of contingent consideration                                                                                                                                 6,800                           (22,600)

       Other expense, net                                                                                                                                                                   (658)                           (1,721)

       Total Other Income (Expense), net                                                                                                                                                    6,045                           (24,251)

       Loss Before Income Taxes                                                                                                                                                          (31,325)                         (100,252)

       Income Tax Provision (Benefit)                                                                                                                                                       7,329                            (3,854)

                Net Loss - GAAP                                                                                                                                                     $(38,654)                         $(96,398)

                (Loss) Earnings Per Share:

       GAAP loss per share - basic and diluted                                                                                                                                            $(0.24)                           $(0.62)

       Non-GAAP earnings (loss) per share - basic and diluted                                                                                                                               $0.01                            $(0.17)

                Weighted Average Number of Ordinary Shares Outstanding:

       Basic and diluted - GAAP and Non-GAAP                                                                                                                                              158,095                            156,336

       Basic - Non-GAAP                                                                                                                                                                   158,095                            156,336

       Diluted - Non-GAAP                                                                                                                                                                 159,038                            156,336

       An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income (loss) is as follows:

                Net Loss - GAAP                                                                                                                                                     $(38,654)                         $(96,398)


       Share-based compensation expense                                                                                                                                                    19,812                             24,616

       Depreciation expense                                                                                                                                                                10,881                              9,690

       Amortization expense                                                                                                                                                                 9,728                              9,952

       Income tax effect related to reconciling items                                                                                                                                       5,920                              2,972

       Non-cash net interest expense                                                                                                                                                          167                                169

       Change in the fair value of warrants and equity method investments                                                                                                                                                       433

       Acquisition of IPR&D                                                                                                                                                                   674

       Change in the fair value of contingent consideration                                                                                                                               (6,800)                            22,600

                Non-GAAP Net Income (Loss)                                                                                                                                             $1,728                          $(25,966)

                Condensed Consolidated Balance Sheets                                                                                                         
         March 31,              
        December 31,

                (In thousands)                                                                                                                                                           2020                               2019


       Cash, cash equivalents and total investments                                                                                                                                      $549,738                           $614,370

       Receivables                                                                                                                                                                        246,716                            257,086

       Contract assets                                                                                                                                                                     14,199                              8,386

       Inventory                                                                                                                                                                          109,314                            101,803

       Prepaid expenses and other current assets                                                                                                                                           46,361                             59,716

       Property, plant and equipment, net                                                                                                                                                 362,539                            362,168

       Intangible assets, net and goodwill                                                                                                                                                233,788                            243,516

       Other assets                                                                                                                                                                       263,291                            158,358

                Total Assets                                                                                                                                                       $1,825,946                         $1,805,403

       Long-term debt - current portion                                                                                                                                                    $2,843                             $2,843

       Other current liabilities                                                                                                                                                          337,006                            388,269

       Long-term debt                                                                                                                                                                     273,751                            274,295

       Contract liabilities - long-term                                                                                                                                                    21,156                             22,068

       Other long-term liabilities                                                                                                                                                        128,172                             32,486

       Total shareholders' equity                                                                                                                                                       1,063,018                          1,085,442

                Total Liabilities and Shareholders' Equity                                                                                                                         $1,825,946                         $1,805,403

       Ordinary shares outstanding (in thousands)                                                                                                                                         158,685                            157,779

              This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in
    Alkermes plc's Quarterly Report on Form 10-Q for the three months ended March 31, 2020, which the company intends to file in April 2020.

Alkermes Contacts:
For Investors: Sandy Coombs +1 781 609 6377
For Media: Eva Stroynowski +1 781 609 6823

View original content to download multimedia:

SOURCE Alkermes plc